English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

equate renal function or a known history of mild cardiac dysfunction or peripheral arterial disease? Or should the regimen simply not be administered to the elderly patient due to the unknown risks versus the benefits in this population? It is also reasonable, in the absence of specific attention to the elderly, to inquire if we even know how the oncology community (outside the narrow confines of a clinical trial) actually manages this patient population. For example, do such patients undergo the same surgery suggested as being beneficial in trials that have focused on the younger patient population? Is potentially moderately toxic ‘adjuvant therapy’ to be recommended for patients where the risk-to-benefit ratio might be different from that identified in evidence-based trials that included a limited (and likely inadequate) proportion of patients defined as being ‘elderly’? In this issue of Oncology , two papers appear that directly address the concerns highlighted in this commentary. The manuscript by Palaia et al. [1] explores the issue of the administration of cytotoxic chemotherapy in patients with gynecologic malignancies (ovarian, endometrial or cervical) who are ‘very elderly’ ( ≥ 75 years of age). In this retrospective analysis (n = 49) approximately one half of the population initially received full-dose cytotoxOne of the most serious recognized deficiencies in the cancer clinical trials paradigm, particularly within studies designed to achieve regulatory approval of new antineoplastic pharmaceutical agents, is the distressing but often rather ‘routine’ exclusion of the more elderly patient population. This concern is magnified by the observation that cancer is largely (although certainly not exclusively) associated with the aging process, with the recognized risk of malignant disease (both for an individual and for the entire population) increasing with age. Optimal management of cancer in the very elderly can be quite problematic and often due simply to a profound lack of objective data in this large and growing population of patients. For example, if a new antineoplastic agent or novel combination chemotherapy is reported in the peerreviewed literature to be effective in patients with a particular tumor type, but the median age of the patients treated on the phase-3 randomized trial demonstrating this outcome was more than 20 years younger than the patient in the oncologist’s office today to discuss disease management, how should these data be appropriately utilized to inform the decision-making process? Should the treatment regimen be modified (likely a dose reduction) in some manner due to the ‘physiologic age’ of this patient and concerns for the presence of inadPublished online: August 30, 2013

Management of Cancer in the Elderly: An Essential Need for More Clinically Relevant Data